Indication and Limitations of Use
Rayaldee® (calcifediol) extended-release 30 mcg capsules is indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Rayaldee is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.
This website is intended for US Healthcare Professionals

OPKO Connect provides comprehensive support

Patient assistance programs

For patients identified as not having affordable
access to Rayaldee therapy, OPKO offers a
free drug patient assistance program;
eligibility criteria apply and annual
re-enrollment is required.

Copay assistance

With this program, eligible
commercially insured patients can fill
their Rayaldee prescription for no more
than $5 per month until the annual
maximum limit is reached.

Starter dose program

This program provides a one-time-only free,
14-day supply of product to eligible patients
whose initial Rayaldee coverage determination
is delayed more than 5 days based on payer
review timelines.

Prior authorization support

Can assist with any insurer-required PAs
for Rayaldee on behalf of patients.

For information on how to request
exception coverage for Medicare Part D beneficiaries please visit www.cms.gov.
OPKO Connect services are available
by phone at 844-414-6756
Monday through Friday, 8 AM-8 PM ET